Survivin and HLA-I expression predicts survival of patients with clear cell renal cell carcinoma.
Altered expression of survivin and leukocyte antigen class I (HLA-I) proteins is associated with tumor progression. This study investigated their expressions in clear cell renal cell carcinoma (ccRCC) tissues for association with a clinical significance of ccRCC patients. Ninety ccRCC and 20 normal tissue samples (i.e., control) were immunohistochemically stained for survivin and HLA-I expression for an association with clinicopathological data and survival of ccRCC patients. Survivin protein was expressed in 82.2 % (74/90) of ccRCC tissue samples compared to 0 % in the normal tissues, and HLA-I protein was expressed in 90 % (18/20) of the normal tissues vs. 67.8 % (61/90) in ccRCC samples. Survivin expression was associated with tumor grade, stage, and lymph node metastasis (p = 0.000, p = 0.016, and p = 0.001, respectively). Conversely, lost HLA-I expression did not have any associations with clinicopathological data (p > 0.05). Survivin-negative patients had a higher tumor-free survival rate than patients with survivin expression (p = 0.037). Patients with normal HLA-I levels had a higher tumor-free survival rate than those with reduced HLA-I levels (p = 0.02). The uni- and multivariate analyses indicated that expression of survivin and HLA-I, individually and in combination, was an independent predictor for survival of ccRCC patients. Overexpression of survivin but reduced HLA-I expression is useful in the prediction of tumor-free survival of ccRCC patients.
Department of Urology, Xiangya Hospital, The Central South University, 87 Xiangya Road, 410008, Changsha, Hunan, China.
Sulai
S
Liu
Lin
L
Qi
Qiuxia
Q
Yu
Yinghui
Y
Song
Weiqing
W
Han
Xiongbing
X
Zu
Shusuan
S
Jiang
Jinyang
J
Yuan
Fuhua
F
Zeng
Yu
Y
Xie
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000737:chemistry / Q000401:mortality* / Q000473:pathology; D005260:Female; D015395:Histocompatibility Antigens Class I / Q000032:analysis* / Q000502:physiology; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000032:analysis* / Q000502:physiology; D007680:Kidney Neoplasms / Q000737:chemistry / Q000401:mortality* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D000077022:Survivin
C107489:BIRC5 protein, human; D015395:Histocompatibility Antigens Class I; D051034:Inhibitor of Apoptosis Proteins; D000077022:Survivin